Approval is not the end of a drug's computational story. It is the beginning of a new chapter: monitoring real-world safety at a scale and diversity that no clinical trial can match, detecting unexpected interactions as co-prescription patterns evolve, and managing ongoing pharmacovigilance obligations that persist for the life of the product.
Real-World Safety Signal Detection
Post-market pharmacovigilance relies on spontaneous adverse event reporting — data collected from healthcare providers, patients, and manufacturers through systems like the FDA Adverse Event Reporting System (FAERS). This data is large, noisy, and requires computational analysis to identify meaningful signals against the background of expected event rates.
BioMate integrates FAERS signal analysis, applying standard disproportionality methods to identify adverse event-drug pairs that occur more frequently than expected given the reporting patterns of the full database. Signals are contextualized against the known mechanism of action, the drug class, and the approved indication — distinguishing expected on-target effects from unexpected safety findings that warrant follow-up.
Drug-Drug Interaction Monitoring
As an approved drug enters clinical use, its co-prescription landscape evolves. Patients may be started on new medications that interact with its metabolic pathways, altering exposure in ways that were not anticipated during development. BioMate integrates drug combination safety checking and CYP450 DDI analysis — using established interaction databases and pharmacokinetic modeling — allowing teams to proactively assess combination risks as new co-medication questions arise.
"Post-market surveillance is an ongoing obligation, not a one-time event. The tools that support it should be as accessible as the tools that supported development."
Pharmacogenomics in Post-Market Practice
Real-world populations are more genetically diverse than clinical trial populations. After approval, PGx data from real-world patients can reveal subgroups with systematically different exposure profiles, efficacy outcomes, or adverse event rates. BioMate supports PGx reporting that can inform label updates, risk management strategies, and companion diagnostic development — translating real-world genetic data into actionable clinical guidance.
Further reading: FDA Adverse Event Reporting System (FAERS), EMA pharmacovigilance guidelines, WHO pharmacovigilance programme, and openFDA adverse event API.
Post-market safety monitoring, drug interaction surveillance, and adverse event signal detection require the same rigor as clinical development — with the additional complexity of operating at real-world scale. BioMate provides the computational tools to meet that obligation efficiently and consistently.